The objectives of this study were to describe the durability of response, following achievement of near-complete skin clearance (PASI90), and to identify patient characteristics or clinical factors associated with loss of near-complete skin clearance among patients with psoriasis treated with biologic therapies from the CorEvitas Psoriasis Registry.

Evidence for the durability of near-complete skin clearance for patients using biologic therapies has come primarily from randomized clinical trials, not necessarily reflecting the clinical experience of patients with psoriasis; few real-world data on the topic are available.

Among real-world patients with psoriasis in this study who achieved near-complete skin clearance (PASI90) with systemic biologic therapy, about one-quarter lost response at 6 months (27%), and half lost response at 18 months (50%) following achievement of PASI90.

Non-White race, full-time employment, greater body weight, concomitant psoriatic arthritis, prior use of biologics, and clinically meaningful skin symptoms, including itch and skin pain, were associated with a decreased likelihood of maintaining a treatment response that included near-complete skin clearance.

Dermatologists may consider focusing on patient-reported symptoms as a part of any intervention designed to reduce the likelihood of loss of response to biologic therapies.